Obseva SA (NASDAQ:OBSV) has received an average recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $34.00.
A number of research firms have recently weighed in on OBSV. Zacks Investment Research upgraded shares of York Water from a “sell” rating to a “hold” rating in a research report on Saturday, June 1st. ValuEngine downgraded shares of Valero Energy from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Wedbush began coverage on shares of Millendo Therapeutics in a research report on Thursday, July 18th. They issued an “outperform” rating and a $24.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th.
Shares of NASDAQ OBSV traded down $0.35 during midday trading on Friday, reaching $9.70. The company’s stock had a trading volume of 1,958 shares, compared to its average volume of 39,516. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.02. Obseva has a fifty-two week low of $9.19 and a fifty-two week high of $19.40. The stock’s 50 day moving average price is $10.80. The firm has a market cap of $459.32 million, a P/E ratio of -5.15 and a beta of 0.93.
Obseva (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Sell-side analysts anticipate that Obseva will post -2.32 earnings per share for the current year.
A number of large investors have recently made changes to their positions in OBSV. Fosun International Ltd bought a new position in Obseva in the first quarter valued at approximately $2,494,000. Dimensional Fund Advisors LP grew its stake in shares of Obseva by 274.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock worth $893,000 after purchasing an additional 51,733 shares during the last quarter. Wedbush Securities Inc. grew its holdings in shares of Obseva by 86.1% during the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock valued at $496,000 after purchasing an additional 17,950 shares during the last quarter. Jane Street Group LLC bought a new stake in Obseva in the 4th quarter worth $218,000. Finally, United Services Automobile Association boosted its stake in shares of Obseva by 132.3% during the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock valued at $335,000 after purchasing an additional 15,080 shares in the last quarter. 63.58% of the stock is currently owned by institutional investors and hedge funds.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: How a Put Option Works
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.